Provided herein are zymogen activating molecules such as zymogen activating peptides, and methods of identifying and using these zymogen activating molecules such as zymogen activating peptides.
This type of inactive precursor to an enzyme is known as a zymogen.
This type of inactive precursor to an enzyme is known as a zymogen.
Cloned novel cDNA from the locus adds 34 amino acid residues to the N-terminus of GrB zymogen.
In a zymogen, a peptide blocks the active site of the enzyme.
Thus, this series of zymogen activation constructs represents a significant system for the analysis and characterization of serine protease gene products.
Nota bene: The terms "chief cell" and "zymogenic cell" are often used without the word "gastric" to name this type of cell.
The terms "chief cell" and "zymogenic cell" are often used without the word "gastric" to name this type of cell.
The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition.
The 92 kDa zymogen of gelatinase B and active gelatinase B are markers of neuropathologies associated with disruption of the blood/brain barrier.
Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided.
Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content.
Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content.
Provided herein are type II transmembrane serine protease 10 (MTSP10) polypeptides.
In particular modified Factor X polypeptides, which includes the Factor X zymogen, Factor Xa and other forms of Factor X, and uses thereof are provided.
Modified therapeutic proteins are provided.
The advantages of the expression vector of the invention are demonstrated using Factor XIII which is the last zymogen to be activated in the vertebrate blood coagulation cascade.
Provided herein are antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human activated Protein C (aPC) with minimal binding to its zymogen Protein C (PC).
In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention.
The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half- life of said derivatives.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод